NCT06746688 - A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2 Expressing Metastatic Breast Cancer. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 3, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Breast CancerBreast Cancer Metastatic

Interventions

BIOLOGICAL

ES2B-C001

Vaccine; Administration with or without \[adjuvant\] every third week for a total of five vaccinations.

OTHER

ISA 51 VD

Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations.

Trial Locations (1)

RECRUITING

Medical University Of Vienna, Vienna